Jean Jacques Bienaime - Jan 8, 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Director
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Jan 8, 2024
Transactions value $
-$678,747
Form type
4
Date filed
1/11/2024, 02:40 PM
Previous filing
Feb 12, 2024
Next filing
Feb 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Small acquisition under Rule 16a-6 $4.95K +50 +0.01% $99.05 425K Jan 8, 2024 Direct F1
transaction BMRN Common Stock Options Exercise $631K +10K +2.35% $63.10 435K Jan 9, 2024 Direct F2
transaction BMRN Common Stock Sale -$982K -10K -2.3% $98.19 425K Jan 9, 2024 Direct F2
transaction BMRN Common Stock Options Exercise $631K +10K +2.35% $63.10 435K Jan 10, 2024 Direct F2
transaction BMRN Common Stock Sale -$964K -10K -2.3% $96.38 425K Jan 10, 2024 Direct F2
holding BMRN Common Stock 247K Jan 8, 2024 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 Jan 8, 2024 Shares held as UTMA custodian for child 1
holding BMRN Common Stock 100 Jan 8, 2024 Shares held as UTMA custodian for child 2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -10K -5.52% $0.00 171K Jan 9, 2024 Common Stock 10K $63.10 Direct F3
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -10K -5.85% $0.00 161K Jan 10, 2024 Common Stock 10K $63.10 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 50 shares, with the reporting person's sale of shares at a price of $98.19 on January 9, 2024. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
F2 Trade made pursuant to a 10b5-1 plan executed on August 7, 2023.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.